Analytical Methods View Article Online PAPER Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Cite this: Anal. Methods, 2013, 5, 5644 View Journal | View Issue Simultaneous determination of metolazone and spironolactone in raw materials, combined tablets and human urine by high performance liquid chromatography M. I. Walash, N. El-Enany, M. I. Eid and M. E. Fathy* A new, specific and sensitive reversed-phase high performance liquid chromatographic method was developed for the simultaneous determination of two diuretic drugs; metolazone (MET) and spironolactone (SPL). Good chromatographic separation was achieved within 5.0 min on 150 mm 4.6 mm i.d., 5 mm particle size Spherisorb-ODS 2 C18 column. A mobile phase containing a mixture of methanol and 0.02 M phosphate buffer (70 : 30) v/v at pH 3.0 was used. The analysis was performed at a flow rate of 1 mL min1 with UV detection at 235 nm. Xipamide (XPM) was used as an internal standard (IS). The proposed method was rectilinear over the ranges of 0.05–1.0 mg mL1 and 0.5–10.0 mg mL1 with limits of detection (LOD) of 0.009, 0.04 ng mL1 and limits of quantification (LOQ) of 0.03, 0.11 mg mL1 for MET and SPL, respectively. The suggested method was successfully applied for the simultaneous analysis of the studied drugs in their laboratory prepared mixtures, single tablets and coformulated tablets. The method was further extended to the determination of both drugs in spiked Received 5th July 2013 Accepted 11th August 2013 human urine. The mean percentage recoveries of MET and SPL in spiked human urine were 99.33 2.37 and 99.72 3.27, respectively. The proposed method was also applied for the determination of the studied drugs in the presence of some co-administered or co-formulated drugs without any interference. DOI: 10.1039/c3ay41110a www.rsc.org/methods Statistical evaluation and comparison of the data obtained by the proposed and comparison methods revealed no significant difference between the two methods regarding accuracy and precision. Introduction Metolazone (Fig. 1a), 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2methylphenyl)-4-oxo-6-quinazolinesulfonamide,1 is a diuretic with similar actions and uses to those of the thiazide diuretics. It is orally administered for treatment of edema associated with heart failure and for management of hypertension.2 Spironolactone (Fig. 1b), (7a,17a)-7-(acetylthio)-17-hydroxy-3-oxopregn-4-ene-21-carboxylic acid g-lactone,1 is an aldosterone antagonist. It acts as a potassium-sparing diuretic, increasing sodium and water excretion and reducing potassium excretion. Spironolactone is used in the management of heart failure, and for refractory edema associated with liver cirrhosis. It is frequently given thiazide diuretics such as furosemide, or similar diuretics, where it adds to their natriuretic but diminishes their kaliuretic effects. Hence, potassium is conserved in those who are at risk from hypokalemia.2 A new combination dosage form of metolazone and spironolactone is indicated for the treatment and management of oedema and hypertension. Department of Analytical Chemistry, Faculty of Pharmacy, University of Mansoura, 35516, Mansoura, Egypt. E-mail: [email protected]; Fax: +20 502247496 5644 | Anal. Methods, 2013, 5, 5644–5656 Metolazone and spironolactone are official drugs in the United States Pharmacopoeia (USP),3 the British Pharmacopoeia (BP),4 and in the Europium Pharmacopoeia.5 Reviewing the literature revealed that several methods; such as spectrophotometric,6–10 HPTLC,11,12 and liquid chromatography3,13–15 were used for the determination of metolazone in pharmaceutical preparations either alone6–8,14 or in combination with losartan,13 spironolactone7,9 or Fig. 1 The structural formulae of the studied drugs, (a) metolazone, (b) spironolactone. This journal is ª The Royal Society of Chemistry 2013 View Article Online Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Paper Analytical Methods Fig. 2 Typical chromatogram of laboratory prepared mixture; (A) metolazone (1.0 mg mL1) and spironolactone (10.0 mg mL1) (in 1 : 10 ratio); (B) metolazone (0.5 mg mL1) and spironolactone (10.0 mg mL1) (in 1 : 20 ratio). Under the described chromatographic conditions: a: solvent front; b: metolazone; c: xipamide (2 mg mL1); d: spironolactone. ramipril.12,15 On the other hand, few methods have been reported for the determination of metolazone in biological samples. These methods include: HPLC for the determination of metolazone either alone,16–19 or with furosemide.20 Also, liquid chromatography-tandem mass spectrometry (LCMS),21–24 has been reported for the analysis of metolazone in human plasma or blood. Regarding spironolactone, a good guide to the work published is presented as the comprehensive monographs in the series of Analytical Proles of Drug Substances25 and Excipients.26 The most recently published articles about SPL include: Table 1 Optimization of the chromatographic conditions for separation of metolazone and spironolactone mixture by the proposed HPLC methoda Parameter pH of the mobile phase Ratio of organic modier A/B Ionic strength of phosphate buffer, M Flow rate (mL min1) a A: spectrophotometry,4,7,9,27 TLC,28 liquid chromatography,3,28–33 and LC-MS/MS.34 Metolazone and spironolactone are co-formulated in medicinally recommended ratios of 1 : 10 and 1 : 20, respectively. Up to now, only two spectrophotometric methods7,9 were published concerning the simultaneous determination of both drugs in pharmaceutical preparations. However, nothing has been published for simultaneous analysis of MET and SPL in human urine. Umadevi and Vetrichelvan7 determined MET and SPL over concentration ranges of 0.5–2.5 mg mL1 and phosphate buffer. B: Mass distribution ratio ðDm Þ ¼ methanol, 2.6 3.0 3.5 4.0 5.0 6.0 7.0 25/75 30/70 35/65 40/60 0.01 0.02 0.04 0.06 0.1 0.6 0.8 1.0 1.2 1.4 where: No. of theoretical plates (N) Mass distribution ratio (Dm) MET SPL MET SPL 1171 1456 1371 1281 1287 1347 1299 1433 1472 1490 1445 1436 1452 1433 1429 1483 1586 1439 1460 1202 1022 2275 2594 2496 2450 2456 2972 2678 2643 2567 6540 8505 2339 2585 2456 2527 2575 2873 2656 2544 2314 2040 0.377 0.363 0.365 0.366 0.298 0.379 0.359 0.243 0.362 0.504 0.803 0.325 0.367 0.359 0.362 0.349 0.367 0.363 0.365 0.363 0.362 2.347 2.137 2.095 2.148 1.664 1.984 1.786 1.185 2.129 2.890 5.741 2.012 2.154 2.063 2.019 2.076 2.104 2.089 2.116 2.083 2.079 number of tR tm Dm2 . Relative retention ðaÞ ¼ . tm Dm1 This journal is ª The Royal Society of Chemistry 2013 theoretical plates Resolution (Rs) Relative retention (a) 8.645 6.225 8.903 6.100 7.916 5.739 8.582 5.869 7.665 5.584 8.866 5.235 8.296 4.975 6.388 4.876 8.889 5.881 13.932 5.734 20.706 7.149 8.695 6.191 8.946 5.869 8.716 5.746 8.592 5.577 9.03 5.948 9.345 5.733 8.925 5.755 8.906 5.797 8.292 5.738 7.696 5.743 2 tR 2DtR ðNÞ ¼ 5:54 . Resolution ðRÞ ¼ . Wh=2 W1 þ W2 Anal. Methods, 2013, 5, 5644–5656 | 5645 View Article Online Analytical Methods Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Table 2 Paper Analytical performance data for the determination of the studied drugs by the proposed method Parameter MET SPL Linearity range (mg mL1) Intercept (a) Slope (b) Correlation coefficient (r) S.D. of residuals (Sy/x) S.D. of intercept (Sa) S.D. of slope (Sb) Percentage relative standard deviation, % RSD Percentage relative error, % error Limit of detection, LOD (mg mL1) Limit of quantitation, LOQ (mg mL1) 0.05–1.0 3.80 103 1.115 0.9999 3.80 103 2.90 103 4.70 103 0.843 0.343 0.009 0.03 0.5–10.0 3.20 103 0.373 0.9999 6.60 103 4.20 103 8.10 104 0.570 0.233 0.04 0.11 5–25 mg mL1, respectively. Also, Chaudhary9 estimated MET and SPL over concentration ranges of 1–5 mg mL1 and 5– 25 mg mL1, respectively. Therefore, the proposed method (which assayed MET and SPL over concentration ranges of 0.05–1.0 mg mL1 and 0.5–10.0 mg mL1, respectively) is considered 10 times more sensitive than the previously reported methods.7,9 In addition, the proposed method allows the simultaneous determination of both drugs in their laboratory prepared mixtures, co-formulated tablets considering two pharmaceutical ratios 1 : 10 and 1 : 20; unlike the reported methods7,9 which determine both drugs taking only one pharmaceutical ratio; 1 : 10 (ref. 7) or 1 : 20.9 Moreover, the proposed method was applied to the analysis of both drugs in Table 3 spiked human urine. These facts added to the inherent advantages of HPLC over spectrophotometry regarding high resolution and high sensitivity. In the present work, an efficient HPLC method with UV detection was utilized for the simultaneous analysis of MET and SPL with good resolution and in a short chromatographic run; less than 6 min. This method could be applied for the quantitative determination of the studied drugs in single and coformulated tablets, as well as in human urine. No interference was encountered from other co-administered and co-formulated drugs such as furosemide, hydrochlorothiazide, propranolol, losartan, ramipril, bumetanide, fosinopril, lisinopril, enalapril, captopril and aspirin. Assay results for the determination of the studied drugs in pure form by the proposed and comparison methodsa Proposed method Compound MET Comparison method7 Amount taken (mg mL1) Amount found (mg mL1) 0.05 0.20 0.40 0.60 0.80 1.00 0.049 0.199 0.399 0.603 0.804 0.995 Mean S.D. t-Test F-Test SPL 40.0 80.0 160.0 320.0 400.0 800.0 Mean S.D. t-Test F-Test a 40.50 79.60 161.50 316.30 401.60 800.30 % Found % Found 98.20 99.65 99.83 100.43 100.54 99.55 99.70 0.84 1.290 (2.306) 1.551 (5.409) 101.25 99.50 100.94 98.84 100.40 100.04 100.02 0.57 0.349 (2.306) 2.430 (5.409) 100.00 101.85 99.38 100.66 100.47 1.06 99.18 100.55 101.21 99.77 100.18 0.89 N.B. Each result is the average of three separate determinations. The gures between parentheses are the tabulated t and F values at P ¼ 0.05.35 5646 | Anal. Methods, 2013, 5, 5644–5656 This journal is ª The Royal Society of Chemistry 2013 View Article Online Paper Table 4 Analytical Methods Precision data for the determination of the studied drugs by the proposed methoda MET concentration (mg mL1) Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Parameters Intraday % Found Inter-day (x) S.D. % RSD % Error % Found (x) S.D. % RSD % Error a SPL concentration (mg mL1) 0.20 0.40 0.60 2.0 4.0 6.0 98.87 100.02 100.44 99.78 0.81 0.82 0.47 101.95 96.84 100.85 99.88 2.69 2.69 1.56 97.72 100.45 98.98 99.05 1.37 1.38 0.80 100.61 102.55 101.27 101.48 0.99 0.97 0.56 101.08 100.27 98.67 100.01 1.23 1.23 0.71 99.02 98.00 100.19 99.07 1.10 1.11 0.64 99.95 101.78 99.93 100.55 1.06 1.06 0.61 101.95 102.74 99.94 101.54 1.44 1.42 0.82 99.14 99.76 98.44 99.11 0.66 0.67 0.39 98.66 100.29 100.77 99.91 1.11 1.11 0.64 101.08 99.94 99.64 100.22 0.76 0.76 0.44 99.58 103.14 100.82 101.18 1.81 1.79 1.03 N.B. Each result is the average of three separate determinations. Table 5 Robustness of the proposed method using metolazone (0.5 mg mL1) and spironolactone (5.0 mg mL1)a Parameter Amount found (mg mL1) % Found MET SPL MET SPL 5.017 5.090 4.942 100.91 98.79 102.22 100.64 1.73 1.72 0.99 100.34 101.80 98.83 100.32 1.49 1.48 0.85 5.037 4.940 4.988 98.81 98.49 100.73 99.34 1.21 1.22 0.70 100.74 98.80 99.75 99.76 0.97 0.97 0.56 5.067 5.021 4.950 99.28 100.66 99.80 99.91 0.71 0.71 0.40 101.33 100.42 99.00 100.25 1.17 1.17 0.68 Methanol ratio, % 69 0.505 70 0.494 71 0.511 (x) S.D. % RSD % Error pH 2.9 3.0 3.1 (x) S.D. % RSD % Error 0.494 0.492 0.504 Buffer strength, M 0.01 0.496 0.02 0.503 0.04 0.499 (x) S.D. % RSD % Error a N.B. Each result is the average of three separate determinations. Experimental Apparatus Chromatographic separation was carried out using a Shimadzu LC-20AD Prominence liquid chromatogram equipped with a Rheodyne injector valve with a 20 mL loop and a SPD-20A UV detector. Mobile phases were ltered using 0.45 mm membrane This journal is ª The Royal Society of Chemistry 2013 lters (Millipore, Cork, Ireland) and degassed using a prominence degasser DGU-20A5. Syringe 0.45 mm lters were used for human urine ltration. A Consort NV P-901 calibrated pH-meter (Belgium) was used for pH measurements. Ultrasonic bath (Model: SS 101H 230, USA), vortex mixer (Model: VM-300P, Gemmy Industrial Corp., Taiwan) and centrifuge (Model: 2-16P, Sigma Laborzentrifugen, Germany) were used for human urine sample preparation. Materials and reagents All the chemicals and pharmaceuticals used were of analytical reagent grade and pharmaceutical grade, and the solvents were of HPLC grade. Metolazone was kindly provided by Pharmaceutical Div., Pennwalt Corp., Rochester, N.Y. Spironolactone was kindly provided by Memphis for PHARM. & CHEM. IND. CO., Cairo, Egypt. The purity percentages of MET; 100.45%, and SPL; 99.88%, were established by applying the USP3 and BP4 methods, respectively. Xipamide, used as the internal standard (IS), was provided by Egyptian INT. Pharmaceutical Industries CO. (EIPICO), Egypt. Metenix tablets (Sano-aventis S.A.E, Egypt) and aldactone tablets (KAHIRA PHARM. and CHEM. IND. CO., Cairo, Egypt) were purchased from commercial sources in the local pharmacy. Metenix tablets; batch # 099536, labeled to contain 5 mg metolazone per tablet. Aldactone 25 mg tablets; batch # 1110433-L and aldactone 100 mg; batch # 1110556-L.E. tablets labeled to contain 25 and 100 mg spironolactone, respectively. Laboratory prepared Co-formulated tablets were prepared according to their pharmaceutical ratios, by mixing accurately weighed quantities (equivalent to either 2.5 or 5.0 mg MET) of the mixed contents of 10 powdered metenix tablets with accurately weighed quantities (equivalent to 50.0 mg SPL) of the mixed contents of 10 powdered aldactone tablets. Anal. Methods, 2013, 5, 5644–5656 | 5647 View Article Online Analytical Methods Paper Table 6 Results of MET and SPL solutions stability and mobile phase stability using metolazone (0.5 mg mL1) and spironolactone (5.0 mg mL1) Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Parameter Amount found (mg mL1) % Found MET SPL MET SPL 4.913 4.974 5.062 5.031 5.002 100.71 99.80 100.01 98.38 99.91 99.76 0.85 0.85 0.38 98.25 99.47 101.23 100.61 100.04 99.92 1.14 1.14 0.51 101.38 99.88 100.74 101.51 98.42 100.39 1.28 1.272 0.57 100.89 99.20 100.23 99.03 100.80 100.03 0.88 0.87 0.39 Stock solution prepared Fresh 0.504 2 days ago 0.499 4 days ago 0.500 6 days ago 0.492 10 days ago 0.499 (x) S.D. % RSD % Error Mobile phase prepared Fresh 0.507 3 days ago 0.499 5 days ago 0.504 7 days ago 0.508 10 days ago 0.492 (x) S.D. % RSD % Error 5.045 4.960 5.012 4.952 5.040 Orthophosphoric acid 85% (Riedel-deHa¨ en, Sleeze, Germany). Acetonitrile, ethanol, n-propanol and 2-propanol (SigmaAldrich, Germany). Methanol (Tedia, USA). Sodium dihydrogen phosphate mono hydrate, sodium hydroxide (El-Nasr Pharmaceutical Chemicals Company (ADWIC), Egypt). Human urine was obtained from healthy volunteers. Chromatographic conditions Column: 150 mm 4.6 mm i.d., 5 mm particle size SpherisorbODS 2 C18 column. Mobile phase: a solution consists of a mixture of methanol and 0.02 M sodium dihydrogen phosphate (70 : 30) v/v and the apparent pH was adjusted to 3.0 using orthophosphoric acid. The mobile phase was ltered through a 0.45 mm membrane lter (Millipore, Cork, Ireland). Flow rate: 1 mL min1. UV detector wavelength: 235 nm. Internal standard: xipamide (standard solution containing 400 mg mL1 of xipamide was prepared in methanol and further diluted with methanol to get the appropriate working standard solution). Temperature: room temperature. Standard solutions Stock solutions of 400 mg mL1 MET and 400 mg mL1 SPL were prepared by dissolving 20.0 mg of MET or SPL in 50.0 mL of methanol with the aid of an ultrasonic bath. Working 5648 | Anal. Methods, 2013, 5, 5644–5656 standard solutions were prepared by appropriate dilution of the stock solutions with methanol. Standard laboratory prepared mixture solutions were prepared by mixing appropriate volumes of MET and SPL stock solutions in 50.0 mL volumetric asks and completing to the volume with methanol keeping the pharmaceutical ratios of 1 : 10 and 1 : 20 for MET and SPL, respectively. Solutions of MET and SPL should be stored in light resistant containers;3 this was fullled by covering the asks with aluminium foil. All solutions were stored in the refrigerator at 2 C and found to be stable for at least 10 days without alteration. General recommended procedures Construction of calibration graphs. Accurately measured aliquot volumes of the suitable drug working standard solutions were transferred into a series of 10.0 mL volumetric asks so that the nal concentrations were over the range of 0.05–1.0 mg mL1 for MET and 0.5–10.0 mg mL1 for SPL. To each ask, 0.2 mL of XPM working standard solution was added as internal standard so that its nal concentration was 2.0 mg mL1. Then, the solutions were completed to the volume with the mobile phase at pH 3.0 and mixed well. Aliquots of 20 mL were injected (triplicate) and eluted with the mobile phase under the optimum chromatographic conditions. The average peak area ratios (drug/I.S.) versus the nal concentration of the drugs in mg mL1 were plotted. Alternatively, the corresponding regression equations were derived. Analysis of bulk substances. The method mentioned above was applied to the determination of the purity of raw material for each drug. The percentage recoveries were calculated by referring to the previously prepared calibration graphs or using the corresponding regression equations. Analysis of MET/SPL laboratory prepared mixtures. Aliquots of MET and SPL standard laboratory prepared mixture solutions were transferred into a series of 10.0 mL volumetric asks. The solutions were diluted to the volume with the mobile phase and mixed well. The above procedure described under “Construction of calibration graphs” was then applied. The percentage recoveries were calculated by referring to the calibration graphs, or using the corresponding regression equations. Analysis of the studied drugs in their single tablets. Ten tablets (Metenix, Aldactone 25, or Aldactone 100) were accurately weighed, nely pulverized, and thoroughly mixed. Accurately weighed quantities of pulverized tablets equivalent to 5.0 mg of MET or 20.0 mg of SPL were transferred into 50 mL volumetric asks and about 40.0 mL of methanol were added. The contents of the ask were sonicated for 30 min, completed to the volume with the same solvent and ltered. Aliquots containing suitable concentrations of the studied drugs were analyzed as described under “Construction of calibration graphs”. The nominal contents were calculated either from previously plotted calibration graphs or using the corresponding regression equations. Analysis of the studied drugs in their laboratory prepared coformulated tablets. Accurately weighed quantities of the mixed This journal is ª The Royal Society of Chemistry 2013 View Article Online Paper Table 7 Analytical Methods Assay results for the determination of the studied drugs in their single tablets by the proposed methoda Proposed method Compound Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Metenix 5 mg tablets Mean S.D. % RSD % Error t-Test F-Test Aldactone 25 mg tablets Mean S.D. % RSD % Error t-Test F-Test Aldactone 100 mg tablets Amount taken (mg mL1) Amount found (mg mL1) 0.40 0.60 0.80 1.00 0.389 0.597 0.788 1.001 4.0 6.0 8.0 10.0 4.0 6.0 8.0 10.0 3.936 6.085 7.922 9.844 3.951 6.055 7.891 10.055 Mean S.D. % RSD % Error t-Test F-Test a % Found Comparison method7 97.47 99.59 98.52 100.12 98.53 1.05 1.07 0.62 1.268 1.630 98.39 101.42 99.03 98.44 99.32 1.43 1.44 0.72 0.955 1.168 98.77 100.91 98.64 100.55 99.72 1.18 1.18 0.59 1.788 3.742 101.48 98.00 100.74 100.32 100.14 1.50 (2.447) (9.277) 99.00 100.50 102.00 99.50 100.25 1.32 (2.447) (9.277) 100.20 101.00 101.67 100.75 100.91 0.61 (2.447) (9.277) N.B. Each result is the average of three separate determinations. The gures between parentheses are the tabulated t and F values at P ¼ 0.05.35 contents of 10 prepared co-formulated tablets equivalent to 2.5 or 5.0 mg MET and 50.0 mg SPL were transferred into 100 mL volumetric asks and about 80 mL of methanol were added. The contents of the ask were sonicated for 30 min, completed to the volume with the same solvent and ltered. Aliquots from the ltrate containing suitable concentrations were taken and analyzed as described under construction of the calibration graphs. The nominal contents were calculated either from a previously plotted calibration graph or using the regression equations. Analysis of spiked human urine. In 10.0 mL screw-capped centrifugation tubes, aliquots of human urine (1 mL) were spiked with aliquot volumes of MET and SPL working standard solutions and mixed. Methanol was added to each tube so that the nal volume was 5 mL in each tube. Aer vortex mixing for 10 s, the mixtures were centrifuged at 3500 rpm for 30 min at room temperature and the supernatants were ltered through syringe lters. Aliquots of the supernatants (1 mL) were carefully aspirated, quantitatively transferred into 10 mL volumetric asks and analyzed as described under “Construction of calibration graphs”. A blank experiment was carried out simultaneously. The peak area ratios were plotted versus the concentrations of the drugs in mg mL1. This journal is ª The Royal Society of Chemistry 2013 Results and discussion An HPLC method with UV detection was developed and fully validated for the simultaneous determination of MET and SPL. The proposed method permitted the separation of the two drugs with resolution factors (Rs) ¼ 3.80 (MET in respect to XPM) and 5.44 (SPL in respect to XPM) and selectivity factors (a) ¼ 2.64 (MET in respect to XPM) and 2.17 (SPL in respect to XPM) in a reasonable time less than 5 min. Fig. 2 shows a typical chromatogram for a laboratory prepared mixture of the two drugs under the described chromatographic conditions. The retention times for MET, XPM and SPL were 2.13, 3.12 and 4.75 min, respectively. The proposed method offers high sensitivity as 0.05 mg mL1 of MET and 0.5 mg mL1 of SPL could be detected accurately. It also permitted the quantitation of MET and SPL in single and co-formulated tablets. Moreover, the method was extended to determine both drugs in spiked human urine. Optimization of the chromatographic performance and system suitability The different parameters affecting the chromatographic performance of the studied drugs were carefully studied in Anal. Methods, 2013, 5, 5644–5656 | 5649 View Article Online Analytical Methods Table 8 Paper Assay results for the determination of the studied drugs in their prepared co-formulated tablets by the proposed methoda Comparison method7 Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Proposed method Amount taken (mg mL1) Amount found (mg mL1) % Found Preparation MET SPL MET MET SPL MET SPL Prepared co-formulated tablet (1/10 ratio) 0.40 0.60 0.80 1.0 4.0 6.0 8.0 10.0 0.403 0.593 0.806 0.998 100.85 98.92 100.78 99.8 100.09 0.91 0.91 0.46 0.650 2.332 100.55 99.30 100.25 100.85 100.24 0.67 0.67 0.34 0.145 7.018 100.92 98.27 101.22 99.7 100.03 1.34 1.34 0.67 1.191 1.400 101.17 100.25 99.46 100.9 100.45 0.76 0.76 0.38 1.333 2.143 97.98 101.35 99.66 99.19 99.55 1.40 102.00 101.00 99.50 101.80 101.08 1.14 100.00 99.26 102.99 99.25 100.38 1.78 (2.447) (9.277) 102.78 100.56 100.37 101.67 101.35 1.12 Mean S.D. % RSD % Error t-Test F-Test Prepared co-formulated tablet (1/20 ratio) 0.05 0.10 0.30 0.50 1.0 2.0 6.0 10.0 0.0503 0.0993 0.3008 0.5000 Mean S.D. % RSD % Error t-Test F-Test a SPL 4.037 5.896 8.098 9.970 1.012 2.005 5.968 10.090 % Found (2.447) (9.277) N.B. Each result is the average of three separate determinations. The gures between parentheses are the tabulated t and F values at P ¼ 0.05.34 Table 9 System suitability test parameters for the developed HPLC method Parameter MET SPL No. of theoretical plates, N Capacity factor, k0 Selectivity factor, a (in respect to I.S.) Resolution factor, Rs (in respect to I.S.) % RSD Retention time (tR) 1460 0.36 2.64 3.80 0.843 2.13 2572 2.13 2.17 5.44 0.570 4.75 order to achieve the most suitable chromatographic conditions. The choice was based on the highest number of theoretical plates and the best resolution. Different experimental parameters were changed individually while the others were kept constant. Well-dened symmetrical peaks were obtained aer thorough experimental trials that can be summarized as follows. Choice of column. Three different columns were used for performance investigations, including: 150 mm 4.6 mm i.d., 5 mm particle size Spherisorb-ODS 2 C18 column; Shim-pack VPODS column (250 mm 4.6 mm i.d., 5 mm particle size) and Shim-Pack (150 mm 4.6 mm i.d) CLC-Cyanopropyl-bonded stationary phase. The experimental studies revealed that the rst column was the most suitable one since it produced symmetrical, well-dened peaks with high resolution and high sensitivity within a reasonable analysis time. The second column was not suitable as it showed delayed peaks. The third column produced small, overlapped peaks with low sensitivity. 5650 | Anal. Methods, 2013, 5, 5644–5656 Choice of appropriate wavelength. The UV absorption spectra of the methanolic solution of the studied drugs exhibited maxima at 237 for SPL and 235, 273 and 338 nm for MET. Both drugs show reasonable absorbance at about 235 nm. However, three wavelengths (230, 235, 240) were tried to detect the peaks of both drugs showing the highest sensitivity with a reasonable response. Therefore, The UV detector response was set at 235 nm permitting the determination of both drugs in the recommended ratio. Mobile phase composition. Several modications in the mobile phase composition were performed in order to improve the performance of the chromatographic system. These modications included: the change of the type and ratio of the organic modier, the pH of the mobile phase and the ionic strength of phosphate buffer. The results obtained are shown in Table 1. Type of organic modier. Methanol was replaced by either acetonitrile, ethanol, n-propanol or 2-propanol. Acetonitrile resulted in good resolution of the two drugs but MET was overlapped with the solvent front. Upon using ethanol, the solvent front greatly interfered with the peak of MET, in addition to the poor resolution of MET peak from SPL peak. nPropanol and 2-propanol produced overlapping peaks of MET and SPL. So, methanol was the organic modier of choice giving well resolved, highly sensitive peaks within a reasonable time. Ratio of organic modier. It was observed that the most critical factor for the separation process is the ratio of methanol in the mobile phase, where small variations in such ratio This journal is ª The Royal Society of Chemistry 2013 View Article Online Paper Table 10 Analytical Methods Assay results for the determination of the studied drugs in laboratory prepared mixtures of their pharmaceutical ratiosa Comparison method7 Proposed method Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Amount taken (mg mL1) Amount found (mg mL1) % Found % Found MET/SPL ratio MET SPL MET SPL MET SPL MET SPL 1/10 ratio 0.40 0.60 0.80 1.0 4.0 6.0 8.0 10.0 0.399 0.600 0.791 0.983 3.998 5.978 7.890 10.041 99.89 100.05 98.84 98.27 99.26 0.85 0.86 0.43 0.418 2.073 98.54 100.33 98.22 99.39 99.12 0.95 0.95 0.48 0.679 1.849 99.96 99.64 98.63 100.41 99.66 0.76 0.76 0.38 1.810 2.041 98.71 100.18 100.35 100.41 99.91 0.81 0.81 0.41 1.157 1.749 98.06 100.97 100.00 99.27 99.58 1.23 98.18 99.09 99.39 98.64 98.83 0.53 98.53 101.47 99.02 99.63 99.66 1.29 (2.447) (9.277) 101.00 99.50 102.00 100.25 100.69 1.07 Mean S.D. % RSD % Error t-Test F-Test 1/20 ratio 0.05 0.10 0.30 0.50 1.0 2.0 6.0 10.0 0.049 0.100 0.295 0.497 0.987 2.004 6.021 10.041 Mean S.D. % RSD % Error t-Test F-Test a (2.447) (9.277) N.B. Each result is the average of three separate determinations. The gures between parentheses are the tabulated t and F values at P ¼ 0.05.35 (70 : 30 v/v) caused signicant changes in the resolution and sensitivity of the test solutes. This should be taken into consideration during preparation of the mobile phase. The effect of changing the ratio of organic modier on the selectivity and retention times of the test solutes was investigated using mobile phases containing concentrations of 50– 80% of methanol. It was found that the retention times of both MET and SPL decreased upon increasing the ratio of methanol. However, the decrease in retention time of SPL was more signicant than that of MET. The study revealed that the optimum chromatographic performance was achieved upon using 70% methanol (Table 1). Although a ratio below 70% gave higher numbers of theoretical plates and higher resolution values regarding SPL, it gave unsymmetrical peaks with long unacceptable retention times in addition to diminished sensitivity. Ratios less than 60% resulted in very small and broad peaks of SPL with retarded retention time, whereas ratios higher than 75% resulted in complete overlap of the two drugs and great interference of the solvent front with the peak of MET. Fig. 3 Chromatograms of metolazone and spironolactone in their prepared co-formulated tablets: (A) prepared co-formulated tablet (1 : 10 ratio) (0.6 mg mL1 MET and 6.0 mg mL1 SPL). (B) Prepared co-formulated tablet (1 : 20 ratio) (0.3 mg mL1 MET and 6.0 mg mL1 SPL). a: Solvent front; b: metolazone; c: xipamide (2 mg mL1); d: spironolactone. This journal is ª The Royal Society of Chemistry 2013 Anal. Methods, 2013, 5, 5644–5656 | 5651 View Article Online Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Analytical Methods Paper Fig. 4 Application of the proposed method for the determination of metolazone and spironolactone in spiked human urine. (A) Blank urine under the described chromatographic conditions. (B) Metolazone (0.4 mg mL1) and spironolactone (0.8 mg mL1) in spiked human urine under the described chromatographic conditions. a: Metolazone; b: xipamide(1 mg mL1); c: spironolactone. Table 11 Assay results for the determination of the studied drugs in spiked human urine by the proposed method Parameter MET Mean S.D. % RSD % Error SPL Amount taken (mg mL1) Amount found (mg mL1) 0.1 0.2 0.4 1.0 0.097 0.196 0.409 0.997 0.5 0.8 1.2 1.5 0.478 0.829 1.203 1.489 Mean S.D. % RSD % Error % Found 97.10 98.00 102.48 99.72 99.33 2.37 2.38 1.18 95.70 103.66 100.24 99.27 99.72 3.27 3.28 1.64 a ow rate of 1 mL min1 was found to be the optimal one for good separation in a reasonable time (Table 1). The nature of internal standard. Different internal standards such as indapamide, furosemide, hydrochlorothiazide, xipamide were investigated. Xipamide was the internal standard of choice as it showed good symmetrical and well resolved peaks from the peaks of the studied drugs under the specied chromatographic conditions. Validation of the method Linearity and range. Under the above described experimental conditions, a linear relationship was established by plotting the peak area ratio [drug/I.S.] against the drug concentration. The concentration ranges were found to be 0.05–1.0 mg mL1 for MET and 0.5–10.0 mg mL1 for SPL as cited in Table 2. Linear regression analysis of the data gave the following equations: P ¼ 3.80 103 + 1.115C (r ¼ 0.9999) for MET P ¼ 3.20 103 + 0.373C (r ¼ 0.9999) for SPL Apparent pH. The effect of changing the pH of the mobile phase on the selectivity and retention times of the test solutes was investigated using mobile phases of pH ranging from 2.6– 7.0. The study revealed that the effect of pH of mobile phase was not critical over the studied pH range. It was found that changing the pH did not affect the resolution of both drugs. Also, it was noticed that above pH 3.0, the number of theoretical plates slightly decreased and became quite constant up to pH 7. Table 1 shows that pH 3.0 was the most appropriate one considering different chromatographic parameters. Ionic strength of buffer. The effect of changing the ionic strength of phosphate buffer on the selectivity and retention times of the test solutes was investigated using mobile phases containing a concentration of 0.01–0.1 M of phosphate buffer. It was found that changing the ionic strength of phosphate buffer did not affect the selectivity and retention times of the test solutes (Table 1). However, 0.02 M phosphate buffer was selected to be used throughout the work. Flow rate. The effect of ow rate on the formation and separation of peaks of the studied compounds was studied and 5652 | Anal. Methods, 2013, 5, 5644–5656 where P is the peak area ratio, C is the concentration of the drug in mg mL1 and r is the correlation coefficient. Statistical analysis35 of the data gave high value of the correlation coefficient (r) of the regression equation, small values of the standard deviation of residuals (Sy/x), of intercept (Sa), and of slope (Sb), and small values of the percentage relative standard deviation and the percentage relative error (Table 2). These data proved the linearity of the calibration graphs. Limit of quantitation (LOQ) and limit of detection (LOD). The limit of quantitation (LOQ) was determined by establishing the lowest concentration that can be measured according to ICH Q2R1 recommendations36 below which the calibration graph is non linear. The limit of detection (LOD) was determined by establishing the minimum level at which the analyte can be reliably detected. LOQ ¼ 10Sa/b LOD ¼ 3.3Sa/b where Sa ¼ standard deviation of the intercept of the calibration curve and b ¼ slope of the calibration curve. This journal is ª The Royal Society of Chemistry 2013 View Article Online Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Paper Analytical Methods Fig. 5 Chromatograms showing metolazone and spironolactone with co-administered or co-formulated drugs: a: solvent front; b: metolazone (1 mg mL1); c: spironolactone (10 mg mL1); BUM: 5 mg mL1 bumetanide; LOS: 4 mg mL1 losartan potassium; HCT: 4 mg mL1 hydrochlorothiazide; LIS: 20 mg mL1 lisinopril dihydrate; ENP: 5 mg mL1 enalapril; PRP: 3 mg mL1 propranolol hydrochloride; FUR: 2 mg mL1 furosemide; ASP: 6 mg mL1 aspirin. LOQ and LOD values for MET and SPL by the proposed method are presented in Table 2. LOQ values were found to be 0.03 and 0.11 mg mL1 while LOD values were found to be 0.009 and 0.04 mg mL1 for MET and SPL, respectively. Accuracy and precision. To prove the accuracy of the proposed method, the results of the proposed method were compared with those obtained using the comparison method.7 Statistical analysis of the results obtained using Student's t-test and variance ratio F-test35 revealed no signicant difference between the performance of the two methods regarding accuracy and precision, respectively (Table 3). The comparison method7 described three UV spectroscopic methods for simultaneous estimation of metolazone and spironolactone in combined dosage form. It involves rst derivative spectroscopy using 266 nm and 289 nm as zero crossing points for MET and SPL, respectively. Intra-day precision. Intra-day precision was assessed through replicate analysis of three concentrations of the studied drugs at three successive times within the same day. The results are abridged in (Table 4). Inter-day precision. Inter-day precision was carried out through replicate analysis of three concentrations of the studied drugs on three successive days. The results are summarized in (Table 4). This journal is ª The Royal Society of Chemistry 2013 The relative standard deviations were found to be very small indicating reasonable repeatability and intermediate precision of the proposed method. Robustness of the method. The robustness of the proposed method was evaluated by the maintenance of the peak area with the deliberated changes in the experimental parameters; these parameters include (pH 3.0 0.1), methanol concentration 70 1% (v/v) and buffer strength (0.02 0.01). These minor changes did not greatly affect the peak area of both drugs. The results are abridged in (Table 5). Solution stability and mobile phase stability. The stability of the stock solutions was determined by quantitation of both MET and SPL and comparing the results to freshly prepared solutions. It was found that no signicant change was observed in standard solution response, relative to freshly prepared standard. Similarly, the stability of the mobile phase was checked. The results obtained in Table 6 prove that the sample solution and mobile phase used during the assay were stable up to 10 days. Selectivity. The selectivity of the method was investigated by observing any interference encountered from common tablet excipients such as lactose, starch, magnesium stearate, and talc. It was shown that these compounds did not interfere with the results of the proposed method as shown in Tables 7 and 8. Anal. Methods, 2013, 5, 5644–5656 | 5653 View Article Online Analytical Methods System suitability test (SST) Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Evaluation of SST parameters was performed during the development and optimization of the method (Table 1). Moreover, to ascertain the effectiveness of the nal operating system it was subjected to suitability testing. The test was performed by injecting the standard mixture in triplicate and the parameters were calculated as reported by the USP.3 SST parameters include capacity factor (k0 ), selectivity factor (a), resolution factor (Rs) and column efficiency (number of theoretical plates, N). The nal SST parameters under the optimum chromatographic conditions are abridged in Table 9. Applications Analysis of MET/SPL laboratory prepared mixtures. The proposed method was applied to the simultaneous determination of MET and SPL in laboratory prepared mixtures that medicinally recommended in ratios of 1 : 10 and 1 : 20 (Fig. 2). The concentrations of both drugs in the laboratory prepared mixtures were calculated according to the linear regression equations of the calibration graphs. The proposed method was favorably compared with the comparison method.7 The results obtained are shown in Table 10. Statistical analysis of the results obtained by the proposed and comparison methods proved no signicant difference in the performance of both methods regarding accuracy and precision. Pharmaceutical application Dosage form analysis. The proposed method was successfully applied to the assay of the studied drugs in single tablets. The results of the proposed method were favorably compared with those obtained using the comparison method.7 The results are abridged in Table 7. The proposed method was further applied to the determination of the studied drugs in laboratory prepared co-formulated tablets. The results shown in (Table 8) are in good agreement with those obtained with the comparison method.7 Statistical analysis of the results obtained using Student's t-test and variance ratio F-test35 revealed no signicant difference between the performance of the two methods regarding the accuracy and precision, respectively (Tables 7 and 8). Fig. 3 shows chromatograms indicating good resolved peaks of MET and SPL in their laboratory prepared co-formulated tablets. Biological application. MET is incompletely but fairly readily absorbed aer oral administration. About 80% of a dose is excreted in the urine as unchanged drug in 48 h.37 SPL is rapidly but incompletely absorbed aer oral administration; it is subjected to extensive rst-pass metabolism and enterohepatic circulation. The metabolism of spironolactone is very complex and there are a large number of metabolites. About 25 to 55% of a dose is excreted in the urine in 6 days.37 SPL is excreted 40% unaltered and 60% metabolized to canrenone (major metabolite).38 The high sensitivity of the proposed method could allow the determination of the studied drugs in spiked human urine. Analysis of MET and SPL in spiked human urine. A simple precipitation procedure was adopted for the analysis of MET and SPL in spiked human urine using XPM as an internal standard. 5654 | Anal. Methods, 2013, 5, 5644–5656 Paper Fig. 4 shows MET and SPL peaks obtained from spiked urine analysis. Table 11 shows the results obtained from spiked urine. Under the above described experimental conditions, a linear relationship was established by plotting the peak area ratio against concentration. Linear regression analysis of the data gave the following equations: P ¼ 1.47 102 + 1.23C (r ¼ 0.9998) for MET P ¼ 2.80 103 + 0.38C (r ¼ 0.9988) for SPL where P is the peak area ratio, C is the concentration of the drug in mg mL1 and r is the correlation coefficient. The high value of the correlation coefficient (r) indicates the good linearity of the calibration graph. Co-administered and related drugs. The proposed method allows the determination of the studied drugs in the presence of some co-administered or co-formulated drugs such as; furosemide, hydrochlorothiazide, propranolol, losartan, ramipril, bumetanide, fosinopril, lisinopril, enalapril, captopril and aspirin as shown in Fig. 5. None of the above mentioned drugs interfered with the HPLC assay of the studied drugs except furosemide which overwrote MET peak. Conclusion New simple, accurate and highly sensitive chromatographic method with UV detection was explored for the simultaneous determination of MET and SPL in binary mixtures. The proposed method was found to have limits of detection of 0.009, 0.04 mg mL1 and limits of quantitation of 0.03, 0.11 mg mL1 for MET and SPL, respectively. In addition, it could be applied to the analysis of both drugs in their single and co-formulated dosage forms. The good validation criteria of the proposed method allow its use in quality control laboratories. It also offers the possibility to determine the studied drugs in the presence of the frequently co-administered drugs; furosemide, hydrochlorothiazide, propranolol, losartan, ramipril, bumetanide, fosinopril, lisinopril, enalapril, captopril and aspirin. The proposed procedure, by virtue of its high sensitivity, could be applied to the analysis of MET and SPL in spiked human urine with simple pretreatment procedures. References 1 S. Budavari, The Merck Index, Merck & Co. Inc., Whitehouse Station, New Jersey, USA, 14th edn, 2006, pp. 1059, 1504. 2 S. C. Sweetman, Martindale: The Complete Drug Reference, The Pharmaceutical Press, London, 37th edn, 2011, vol. A, pp. 1469, 1536. 3 The United States Pharmacopoeia XXXIV, The National Formulary XXIX, The US Pharmacopoeial Convention, Rockville, MD, 2011, vol. III, pp. 3506, 4267. 4 The British Pharmacopoeia, Her Magesty's Stationary Office, London, 2010, vol. II, p. 1418, 1976, vol. III, p. 3105. 5 The European Pharmacopoeia VII, Council of Europe: European Directorate for the Quality of Medicines and Healthcare, Strasbourg, 2010, vol. II, pp. 2494, 2976. This journal is ª The Royal Society of Chemistry 2013 View Article Online Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Paper 6 S. Manjunath, S. A. Raju, S. S. Kumar and V. S. Chouhan, Ultra violet and derivative spectrophotometric methods for estimation of Metolazone in pharmaceuticals, Pharma Sci. Monit., 2011, 2, 204–209. 7 B. Umadevi and T. Vetrichelvan, Simultaneous estimation of metolazone and spironolactone in combined tablet dosage form by UV spectroscopy, Int. J. PharmTech Res., 2011, 3, 2068–2074. 8 S. S. Kumar, S. Manjunath, V. S. Chouhan and S. Appalraju, Development and validation of visible spectrophotometric methods for the estimation of metolazone in pharmaceutical dosage forms, Der Pharma Chemica, 2011, 3, 512–516. 9 A. Chaudhary, K. R. Vadalia and P. Thummer, Development and Validation of Ratio Derivative Spectrophotometric for Simultaneous Estimation of Metolazone and Spironolactone in Pharmaceutical Dosage Form, Int. J. Pharm. Sci. Res., 2012, 3, 3999–4003. 10 B. D. Prasad, B. C. Kanth, R. Vasanthi, M. R. Mohan and D. Prabhakar, A Validated UV Spectroscopic Method of Metolazone in Bulk and its Tablet Dosage Forms, Int. J. Life Sci. Biotechnol. Pharma Res., 2012, 3, 154–157. 11 R. Dubey, V. K. Bhusari and S. R. Dhaneshwar, Validated HPTLC method for simultaneous estimation of losartan potassium and metolazone in bulk drug and formulation, Der Pharmacia Lettre, 2011, 3, 334–342. 12 J. A. Wayadande, R. Dubey, V. K. Bhusari and S. R. Dhaneshwar, Validated HPTLC Method for Simultaneous Estimation of Ramipril and Metolazone in Bulk Drug and Formulation, Der Pharmacia Sinica, 2011, 2, 273. 13 R. Dubey, V. K. Bhusari and S. R. Dhaneshwar, Validated RPHPLC Method for Simultaneous Quantitation of Losartan Potassium and Metolazone in Bulk Drug and Formulation, Sci. Pharm., 2011, 79, 545–554. 14 V. Jadhav, P. Mande and V. Kadam, Validation of reverse phase high performance liquid chromatography method of metolazone and its determination in bulk drug and pharmaceutical dosage form, J. Pharm. Res., 2009, 2, 961– 963. 15 G. S. Devika, M. Sudhakar and J. R. Venkateshwara, RPHPLC Method for Simultaneous Estimation of Metolazone and Ramipril in Oral Solid Dosage Form, Int. J. Pharma Bio Sci., 2012, 3, 193–200. 16 B. Babu, S. Muralidharan, S. N. Meyyanathan and B. Suresh, Pharmacokinetic evaluation of metolazone tablets using healthy human volunteers, J. Biomed. Biotechnol., 2010, 2, 015–017. 17 D. Farthing, D. A. Sica, I. Fakhry and T. W. B. Gehr, Novel high-performance liquid-chromatographic method using solid-phase on-line elution for determination of metolazone in plasma and whole blood, J. Chromatogr., B: Biomed. Sci. Appl., 1994, 653, 171–176. 18 D. Farthing, I. Fakhry, T. W. B. Gehr and D. A. Sica, Quantitation of metolazone in urine by high-performance liquid chromatography with uorescence detection, J. Chromatogr., B: Biomed. Sci. Appl., 1990, 534, 228–232. This journal is ª The Royal Society of Chemistry 2013 Analytical Methods 19 C. W. Vose, D. C. Muirhead, G. L. Evans, P. M. Stevens and S. R. Burford, Quantitation of metolazone in plasma and urine by high-performance liquid chromatography with uorescence detection, J. Chromatogr., B: Biomed. Sci. Appl., 1981, 222, 311–315. 20 D. Farthing, T. W. B. Gehr, I. Fakhry and D. A. Sica, Direct injection method for determining furosemide [frusemide] and metolazone in urine using high-performance liquid chromatography and uorescence detection, LC-GC, 1991, 9, 478–480. 21 Y. Jia, Y. Zhang, C. Wang, Z. Wang, Y. Liu, J. Wang and A. Wen, An improved LC-MS/MS method for quantitative determination of metolazone in human plasma and its application to a pharmacokinetic study, Biomed. Chromatogr., 2011, 25, 1138–1143. 22 Y. Qiao, J. Peng, Y. Jia, Z. Ma, Z. Yang, L. Yang and A. Wen, Quantitative determination and pharmacokinetic study of metolazone tablets in human plasma by an improved LCMS/MS, Zhongguo Yaoshi, 2011, 14, 606–609. 23 S. M. N. Roy, K. V. Mangaonkar, S. M. Yetal and S. S. Joshi, LC-MS-MS method for determination of metolazone in human plasma, Eur. J. Chem., 2008, 5, 634–640. 24 G. Wei, S. Xiao and C. Liu, Determination of metolazone in human blood by liquid chromatography with electrospray ionization tandem mass spectrometry, J. Chromatogr., B: Anal. Technol. Biomed. Life Sci., 2007, 845, 169–173. 25 J. L. Sutter and E. P. K. Lau, Analytical Proles of Drug Substances, ed. K. Florey, Academic Press, New York, San Francisco, London, 1975, vol. 4, pp. 438–458. 26 M. H. Al-Hadiya, F. Belal, Y. A. Asiri and O. A. Gubara, Analytical Proles of Drug Substances and Excipients, ed. H. G. Britain, Elsevier Science, USA, 2002, vol. 29, pp. 261–320. 27 H. Patel and S. Solanki, Development and Validation of Spectrophotometric Methods for Simultaneous Estimation of Furosemide and Spironolactone in Combined Tablet Dosage Form, Int. J. Pharm. Pharm. Sci., 2012, 4, 383–386. 28 M. A. Hegazy, F. H. Metwaly, M. Abdelkawy and N. S. Abdelwahab, Validated chromatographic methods for determination of hydrochlorothiazide and spironolactone in pharmaceutical formulation in presence of impurities and degradants, J. Chromatogr. Sci., 2011, 49, 129–135. 29 M. I. Walash, N. El-Enany, M. I. Eid and M. E. Fathy, Micellar High Performance Liquid Chromatographic Determination of Furosemide and Spironolactone in Combined Dosage Forms. Application to Human Plasma, J. Pharm. Res., 2012, 5, 2648–2656. 30 C. Vadloori and V. Tallada, Development and Validation of RP-HPLC Method for Simultaneous Estimation of Spironolactone and Frusemide in Bulk and Pharmaceutical Dosage Forms, J. Pharm. Res., 2012, 5, 3998–4000. 31 B. Maulik, D. Ketan and F. Shital, Development and Validation of RP-HPLC Method for Simultaneous Estimation of Furosemide and Spironolactone in their Combined Tablet Dosage Form, Journal of Pharmaceutical Science and Bioscientic Research, 2012, 2, 144–147. 32 V. R. Ram, P. N. Dave and H. S. Joshi, Development and validation of a stability-indicating HPLC assay method for Anal. Methods, 2013, 5, 5644–5656 | 5655 View Article Online Published on 12 August 2013. Downloaded by RSC Internal on 23/10/2013 15:55:37. Analytical Methods simultaneous determination of spironolactone and furosemide in tablet formulation, J. Chromatogr. Sci., 2012, 50, 721–726. 33 P. B. Deshpande, S. V. Gandhi, N. V. Gaikwad and K. S. Khandagle, A simple and sensitive RP-HPLC method for simultaneous estimation of torsemide and spironolactone in combined tablet dosage form, Acta Chromatogr., 2012, 24, 15–22. 34 L. Vlase, S. Imre, D. Muntean, M. Achim and D. Muntean, Determination of spironolactone and canrenone in human plasma by high-performance liquid chromatography with mass spectrometry detection, Croat. Chem. Acta, 2011, 84, 361–366. 35 J. C. Miller and J. N. Miller, Statistics and Chemometrics for Analytical Chemistry, Pearson Education Limited, Harlow, England, 5th edn, 2005, pp. 39–73, 107–149, 256. 5656 | Anal. Methods, 2013, 5, 5644–5656 Paper 36 ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2(R1), Current Step 4 Version, Parent Guidelines on Methodology Dated November 6 1996, Incorporated in November 2005, http://www.ich.org/LOB/media/MEDIA417.pdf, accessed 15 February, 2008. 37 A. C. Moffat, M. D. Osselton, B. Widdop and L. Y. Galichet, Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material, The Pharmaceutical Press, London, 4th edn, 2011, vol. II, pp. 1698, 2065. 38 O. Hern´ andez, E. Mart´ın, F. Jim´ enez, A. I. Jim´ enez and J. J. Arias, Use of partial least-squares regression for multicomponentdeterminations based on kinetic spectrouorimetric data. Simultaneous determination of canrenone and spironolactone in urine, Analyst, 2000, 125, 1159–1165. This journal is ª The Royal Society of Chemistry 2013
© Copyright 2024